# Methods in ENZYMOLOGY

### Volume 545

Regulated Cell Death Part B: Necroptotic, Autophagic and other Non-apoptotic Mechanisms

Edited by

Avi Ashkenazi James A. Wells Junying Yuan



### METHODS IN ENZYMOLOGY

Regulated Cell Death Part B: Necroptotic, Autophagic and other Non-apoptotic Mechanisms

Edited by

### AVI ASHKENAZI

Cancer Immunology, Genentech, Inc., San Francisco, CA. USA

IAMES AT WELLS -

Departments of Pharmacqutical Chemistry and Cellulat Revolecular Pharmacqlogy, University of Calbornia – San Francisco, CA, USA

### JUNYING YUAN

Department of Cell Biology, Harvard Medical School, Boston, MA, USA





AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK 32 Jamestown Road, London NW1 7BY, UK

First edition 2014

Copyright © 2014, Elsevier Inc. All Rights Reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-12-801430-1

ISSN: 0076-6879

For information on all Academic Press publications visit our website at store.elsevier.com



## METHODS IN ENZYMOLOGY

Regulated Cell Death Part B: Necroptotic, Autophagic and other Non-apoptotic Mechanisms

### METHODS IN ENZYMOLOGY

Editors-in-Chief

### JOHN N. ABELSON and MELVIN I. SIMON

Division of Biology California Institute of Technology Pasadena, California

### ANNA MARIE PYLE

Departments of Molecular, Cellular and Developmental Biology and Department of Chemistry Investigator Howard Hughes Medical Institute Yale University

Founding Editors

SIDNEY P. COLOWICK and NATHAN O. KAPLAN

### CONTRIBUTORS

### Eric H. Baehrecke

Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

### Rhesa Budhidarmo

Department of Biochemistry, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand

### Catherine L. Day

Department of Biochemistry, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand

### Alexei Degterev

Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA

### Paul C. Driscoll

Division of Molecular Structure, Medical Research Council, National Institute for Medical Research, London, United Kingdom

### Peter Geserick

Section of Molecular Dermatology, Department of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Heidelberg, Germany

### Tae-Bong Kang

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel, and Department of Biotechnology, College of Biomedical and Health Science, Konkuk University, Chung-Ju, Republic of Korea

### Maxime J. Kinet

Laboratory of Developmental Genetics, The Rockefeller University, New York, USA

### Andrew Kovalenko

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel

### Martin Leverkus

Section of Molecular Dermatology, Department of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Heidelberg, Germany

### Jenny L. Maki

Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA

### Adam J. Middleton

Department of Biochemistry, Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand

X Contributors

### Charles Nelson

Department of Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA

### Vassiliki Nikoletopoulou

Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology—Hellas, Heraklion, Greece

### Ramon Schilling

Section of Molecular Dermatology, Department of Dermatology, Venereology, and Allergology, Medical Faculty Mannheim, University Heidelberg, Heidelberg, Germany

### Pascal Schneider

Department of Biochemistry, University of Lausanne, Epalinges, Switzerland

### Shai Shaham

Laboratory of Developmental Genetics, The Rockefeller University, New York, USA

### John Silke

The Walter and Eliza Hall Institute of Medical Research, and Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia

### Cristian R. Smulski

Department of Biochemistry, University of Lausanne, Epalinges, Switzerland

### Brent R. Stockwell

Department of Biological Sciences; Department of Chemistry, and Howard Hughes Medical Institute, Columbia University, New York, USA

### Nektarios Tavernarakis

Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology—Hellas, Heraklion, Greece

### Beata Toth

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel

### Domagoj Vucic

Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California, USA

### David Wallach

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel

### Laure Willen

Department of Biochemistry, University of Lausanne, Epalinges, Switzerland

### Adam J. Wolpaw

Residency Program in Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

### Seung-Hoon Yang

Department of Biological Chemistry, The Weizmann Institute of Science, Rehovot, Israel

Contributors

### Junying Yuan

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA

### Wen Zhou

Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA

### **PREFACE**

Cell turnover is a fundamental feature of metazoan biology. Severe damage to cellular integrity usually causes passive, nonregulated cell death. In contrast, more confined disruption can lead to more deliberate cell elimination, through specific mechanisms of Regulated Cell Death. In these two volumes of Methods in Enzymology, we aim to highlight the current molecular understanding of the major processes of Regulated Cell Death and to illustrate basic and advanced methodologies to study them. Volume A focuses on the most extensively studied mode of cell death-apoptosis. Volume B covers several nonapoptotic mechanisms. These include necroptosis, which shares certain signal transduction aspects with apoptosis but is unique in its execution phase, and autophagic cell death, which is an offshoot of autophagy—a more basic prosurvival metabolic adaptation mechanism. Chapters 1-4 cover how to measure necroptosis and various molecular components and complexes that signal this process. Chapter 5 discusses approaches to interrogating interactions between tumor necrosis factor superfamily ligands and receptors. Chapters 6-8 highlight nonapoptotic cell death mechanisms in the model organisms, C. elegans and D. melanogaster. Chapters 9 and 10 discuss structural aspects of death receptor complexes and strategies to study posttranslational modification of downstream signaling components by RING E3 ubiquitin ligases. Finally, Chapter 11 describes a multidimensional profiling approach to studying smallmolecule-induced cell death. We hope these chapters will be both conceptually informative and practically useful for readers interested in the current understanding and the key open questions in each area, as well as in experimental strategies and techniques to interrogate nonapoptotic regulated cell death mechanisms.

> Avi Ashkenazi James A. Wells Junying Yuan

Adam J. Wolpaw and Brent R. Stockwell, Figure 11.6 Comparing and clustering modulatory profiles. (A) Heat map of the similarity matrix showing the Spearman correlation between modulatory profiles of both characterized and uncharacterized lethal compounds. (B) Dendrogram derived from clustering the similarity matrix shown in (A). Five broad clusters are highlighted and lettered. In addition, microtubule destabilizers are shown in black, a cluster that includes three previously uncharacterized compounds. Other features that are not highlighted include clustering of characterized compounds according to their known mechanisms of action—alkylating agents, mitochondrial poisons, topoisomerase inhibitors, histone deacetylase inhibitors, and proteasome inhibitors. Reproduced with permission from Wolpaw et al. (2011) and slightly altered.

### **CONTENTS**

Contributors	
Preface	xiii
1. Assays for Necroptosis and Activity of RIP Kinases	1
Alexei Degterev, Wen Zhou, Jenny L. Maki, and Junying Yuan	
1. Introduction	2
2. Cellular Models of Necroptosis	5
3. Measurement of Necroptotic Cell Death	9
4. Recapitulation of RIP1 Kinase Expression in RIP1-Deficient Jurkat	Cells 16
5. Analysis of Necrosome Complex Formation	18
6. Endogenous RIPK Autophosphorylation Assays	21
7. Analysis of Recombinant RIPK1 Kinase Activity and Inhibition	
by Necrostatins	23
8. Conclusions	28
Acknowledgments	29
References	29
2. IAP Family of Cell Death and Signaling Regulators	35
John Silke and Domagoj Vucic	
1. Identification of IAPs, Structure, and Domain Function	36
2. IAP Proteins and Cell Death Pathways	39
References	55
3. Activation of the NLRP3 Inflammasome by Proteins	
That Signal for Necroptosis	67
Tae-Bong Kang, Seung-Hoon Yang, Beata Toth, Andrew Kovalen	ko,
and David Wallach	
1. Introduction	68
2. Altered Expression or Function of Enzymes That Control Inducti	on
of Necroptosis Results in Altered Generation of IL-1 $\beta$ and IL-18	
by Mouse DCs	69
3. Signaling Proteins Controlling Necroptosis Affect Assembly	
of the NLRP3 Inflammasome	72

	4.	Does the Similarity Between the Regulation of Necroptosis and of	
		Assembly of the NLRP3 Inflammasome Reflect Activation of the	7.5
	_	Inflammasome by Products of Necrotic Cells?	75
		Concluding Remarks	78
		knowledgments	79
	Ref	erences	79
4.		aracterization of the Ripoptosome and Its Components: plications for Anti-inflammatory and Cancer Therapy	83
	Rai	mon Schilling, Peter Geserick, and Martin Leverkus	
	1.	Introduction	84
	2.	The Ripoptosome: Cellular Model Systems to Study Its Formation	87
	3.	Biochemical Analysis of the Ripoptosome: Analysis of Ripoptosome	
		Formation and Identification of Novel Components via Immunoprecipitation	
		and Mass Spectrometry	94
	4.	Outlook: Future Implications of the Function and Regulation	
		of the Ripoptosome	97
	Ref	Ferences	100
5	Int Su	ols and Techniques to Study Ligand–Receptor teractions and Receptor Activation by TNF perfamily Members scal Schneider, Laure Willen, and Cristian R. Smulski	103
	1.	Introduction	104
	2.	Methods	106
	3.	Conclusions	123
	Ac	knowledgments	124
		ferences	124
6		ecrotic Cell Death in <i>Caenorhabditis elegans</i> ssiliki Nikoletopoulou and Nektarios Tavernarakis	127
			120
		Introduction	128
	2.	Necrotic Cell Death Paradigms During <i>C. elegans</i>	100
	2	Development Nandayalanasatal Nassatis Death	130
	3. 4.	Nondevelopmental Necrotic Death  Execution of Necrosis	134 140
	4. 5.	C. elegans as a Model for Human Diseases Entailing Necrosis	140
	6.	Concluding Remarks	147
		knowledgments	149
		ferences	149

Contents

7.	Nor	ncanonical Cell Death in the Nematode Caenorhabditis elegans	157
	Max	ime J. Kinet and Shai Shaham	
	1.	Introduction	158
	2.	Pathological Cell Death Induced by Genome Lesions and	
		Environmental Stress	159
	3.	Developmental Cell Deaths That Do not Follow the Canonical	
		Apoptotic Pathway	168
		Nonapoptotic, Caspase-Independent Linker Cell Death	172
		Conclusion	175
	Ackı	nowledgments	175
		erences	175
8.		ophagy and Cell Death in the Fly	181
	Cha	rles Nelson and Eric H. Baehrecke	
	1.	Introduction	182
	2.	Materials and Methods	184
	3.	Data Analysis and Interpretation	191
	Ack	nowledgments	198
	Refe	erences	198
9.	Str	uctural Studies of Death Receptors	201
	Pau	I C. Driscoll	
	1.	Introduction. Signaling by the Tumor Necrosis Receptor Superfamily	202
	2.	Outline Death Ligand and DR Domain Structure	204
	3.	DR Ectodomain Structure	206
	4.	Physiological Complexes of Death Ligands with DRs	213
	5.	A Decoy Receptor-Ligand Complex	214
	6.	The DR Preligand Association Domain	215
	7.	Death Ligand Structure–Activity Relationships	217
	8.	Structural Analysis of AntiTNF Agents	219
	9.	Structural Analysis of the Blockade of DR Function	220
	10.	DR Cytoplasmic Domains	221
	11.	DD Structure	222
	12.	The DD Superfamily	225
	13.	DD Assembly Revealed by the Structure of the PIDDosome Core	226
	14.	Structural Characterization of CD95:FADD-DD Complexes	228
	15.	Relevance of CD95:FADD-DD Assemblies to Physiological CD95 Signaling	230
	16.	Unanswered Questions and Future Prospects	233
	Ack	nowledgments	234
	Refe	erences	234

viii

	Use of E2~Ubiquitin Conjugates for the Characterization of Ubiquitin Transfer by RING E3 Ligases Such as the Inhibitor	
C	of Apoptosis Proteins	243
A	dam J. Middleton, Rhesa Budhidarmo, and Catherine L. Day	
1	. Introduction	244
2	. Synthesis of E2~Ub Conjugates	246
3	. Characterization of RING-E2~Ub Complexes	251
4	. Conclusion	259
A	cknowledgments	260
F	deferences	260
S	Multidimensional Profiling in the Investigation of Small-Molecule-Induced Cell Death Adam J. Wolpaw and Brent R. Stockwell	265
1	. Introduction	266
2	. Gene Expression Profiling	271
3	. Protein Quantification	277
4	. Gene–Small-Molecule Interactions	280
5	5. Small-Molecule Combination Interactions	282
6	6. Cell Line Viability Profiling	284
7	'. Quantitative Imaging	288
8	B. Modulatory Profiling	290
9	2. Conclusions	296
F	References	297
Auth	or Index	303
Subie	ect Index	331



### Assays for Necroptosis and Activity of RIP Kinases

Alexei Degterev\*, Wen Zhou<sup>†</sup>, Jenny L. Maki\*, Junying Yuan<sup>†,1</sup>

\*Department of Developmental, Molecular & Chemical Biology, Tufts University School of Medicine, Boston, Massachusetts, USA

<sup>†</sup>Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA

<sup>1</sup>Corresponding author: e-mail address: junying\_yuan@hms.harvard.edu

### Contents

1.	Intro	oduction	2
	1.1	Distinguishing features of necroptotic cell death	2
	1.2	Pathways and mediators of necroptosis	3
2.	Cell	ular Models of Necroptosis	5
	2.1	Cell types	5
	2.2	Inducers of necroptosis	7
	2.3	Inhibitors of necroptosis	8
3.	Mea	asurement of Necroptotic Cell Death	9
	3.1	Analysis of viability of FADD-deficient Jurkat cells treated with TNF $lpha$ using	
		CellTiter-Glo assay	9
	3.2	Determination of specific cell death using SYTOX Green assay	10
	3.3	Annexin V/PI assay	11
	3.4	Analysis of ROS increase	12
	3.5	Mitochondrial membrane depolarization	14
	3.6	Analysis of TNF $\alpha$ gene expression changes by qPCR	14
4.	Rec	apitulation of RIP1 Kinase Expression in RIP1-Deficient Jurkat Cells	16
	4.1	Transient transfection	16
	4.2	Generation of stable-inducible cell lines	17
5.	Ana	llysis of Necrosome Complex Formation	18
	5.1	Immunoprecipitation of necrosome complex	18
	5.2	Immunoprecipitation of TNFR1 complex	20
	5.3	Assessment of necrosome formation by fluorescence microscopy	21
6.	End	logenous RIPK Autophosphorylation Assays	21
7.	Ana	lysis of Recombinant RIPK1 Kinase Activity and Inhibition by Necrostatins	23
	7.1	Expression and purification of recombinant RIP1 and RIP3	23
	7.2	Kinase-Glo assay	23
	7.3	HTRF KinEASE assay	25
	7.4	Fluorescence polarization assay	26
	75	Thermomelt assay	27

8. Conclusions	28
Acknowledgments	29
References	29

### **Abstract**

Necrosis is a primary form of cell death in a variety of human pathologies. The deleterious nature of necrosis, including its propensity to promote inflammation, and the relative lack of the cells displaying necrotic morphology under physiologic settings, such as during development, have contributed to the notion that necrosis represents a form of pathologic stress-induced nonspecific cell lysis. However, this notion has been challenged in recent years by the discovery of a highly regulated form of necrosis, termed regulated necrosis or necroptosis. Necroptosis is now recognized by the work of multiple labs, as an important, drug-targetable contributor to necrotic injury in many pathologies, including ischemia—reperfusion injuries (heart, brain, kidney, liver), brain trauma, eye diseases, and acute inflammatory conditions. In this review, we describe the methods to analyze cellular necroptosis and activity of its key mediator, RIP1 kinase.



### 1. INTRODUCTION

### 1.1. Distinguishing features of necroptotic cell death

Discovery of regulated necrosis originates from the observations that "canonical" inducers of apoptosis, such as agonists TNF $\alpha$  family of death domain receptors (DRs), can trigger cell death morphologically resembling necrosis in cells either intrinsically deficient in caspase activation (e.g., mouse fibrosarcoma L929 cells) or under conditions when caspase activation is inhibited (e.g., caspase-8-deficient Jurkat cells or cells treated with pancaspase inhibitor zVAD.fmk) (Holler et al., 2000; Matsumura et al., 2000; Vercammen, Vandenabeele, Beyaert, Declercq, & Fiers, 1997). The lack of caspase activation as well as the absence of other typical features of apoptosis, such as cytochrome  $\epsilon$  release, membrane blebbing, phosphatidylserine (PS) exposure, and intranucleosomal DNA cleavage, served as important initial differentiators between necroptosis and apoptosis (Tait & Green, 2008).

Electron microscopy has also proved very useful in distinguishing necroptosis from apoptosis in morphology. Necroptotic cells are characterized by the lack of typical nuclear fragmentation, swelling of cellular organelles especially mitochondria, and the loss of plasma membrane integrity, whereas apoptotic cells exhibit shrinkage, blebbing, nuclear fragmentation, and chromatin condensation (Degterev et al., 2005). Robust activation of

autophagy is another feature of necroptosis which provides useful means to distinguish this form of cell death *in vitro* and *in vivo* both morphologically (e.g., by EM) and at the molecular level (e.g., by measuring of LC3II formation) (Degterev et al., 2005; Yu et al., 2004). This leads to necroptosis in some cases being referred to as "autophagic cell death," such as zVAD-induced death of L929 cells (Yu et al., 2004). It should be noted, however, that functional role of autophagy varies greatly depending on the specifics of necroptosis activation, with instances where this process promotes, inhibits, or does not affect cell death (Degterev et al., 2005; Shen & Codogno, 2012; Yu et al., 2004). Furthermore, activation of necroptosis-inducing necrosome complex (discussed below) can also happen downstream from autophagosome formation (Basit, Cristofanon & Fulda, 2013).

A detailed comparison of TNF-induced necroptosis and  $\rm H_2O_2$ -induced necrosis was performed by Vanden Berghe et al. (2010). Despite the different kinetics of cellular events including ROS production, mitochondrial polarization changes, and lysosomal membrane permeabilization, the major hallmarks of necroptosis and oxidant-induced necrosis were remarkably similar, leading to an important conclusion that necroptosis is a subtype of necrosis, morphologically indistinguishable from other types of necrosis but defined by a specific mode of activation (discussed below).

Generation of DAMPs as a result of cell lysis is an important consequence of necroptotic death both *in vitro* and *in vivo* (Duprez et al., 2011; Murakami et al., 2013). In addition, recent evidence suggests that synthesis of TNF $\alpha$  occurs independently of cell death as a result of specific signaling by key necroptosis initiator RIP1 kinases (RIPK1) (Christofferson et al., 2012; Kaiser et al., 2013; McNamara et al., 2013). Autocrine TNF $\alpha$  can promote cell death dependent on a cytosolic complex "ripoptosome" consisting of RIPK1, FADD, and caspase–8 (Biton & Ashkenazi, 2011; Hitomi et al., 2008; Kaiser et al., 2013; Tenev et al., 2011). Several instances have also been reported where RIPK1 and RIPK3 promote inflammatory signaling through the production of IL-1 $\alpha$  and IL-1 $\beta$ /IL-18 in the absence of cell death (Kang, Yang, Toth, Kovalenko, & Wallach, 2013; Lukens et al., 2013). These data highlight complex interrelationship between necroptosis and inflammation.

### 1.2. Pathways and mediators of necroptosis

We refer the readers to a number of in-depth reviews on the subject (Christofferson et al., 2012; Christofferson, Li, & Yuan, 2014;